Download PDF
Horm Metab Res 1983; 15(8): 363-366
DOI: 10.1055/s-2007-1018725
© Georg Thieme Verlag, Stuttgart · New York

Inhibitory Effect of Somatostatin-28 on Pancreatic Polypeptide, Glucagon and Insulin Secretion in Normal Man

J. Marco1 , I. Correas1 , M. A. Zulueta1 , E.  Vincent1 , D. H. Coy2 , A. M. Comaru-Schally2 , A. V. Schally2 , M. D. Rodríguez-Arnao3 , A. Gómez-Pan3
  • 1Clínica Puerta de Hierro, Universidad Autonóma de Madrid, Madrid, Spain
  • 2Tulane University School of Medicine, and V.A. Hospital, New Orleans, Louisiana, U.S.A.
  • 3Departamento de Fisiología, Cátedra de Endocrinología Experimental, Universidad Complutense de Madrid, Madrid, Spain
Further Information

Publication History

1982

1982

Publication Date:
14 March 2008 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

We have compared the effects of equimolar doses of intravenous somatostatin-28 (SS-28) and somatostatin-14 (SS-14) (250 μg and 125 μg, respectively) on the secretion of pancreatic polypeptide (PP), glucagon and insulin evoked by a protein-rich meal in normal subjects. Both peptides reduced the fasting plasma levels of these hormones and completely abolished their responses to the alimentary stimulus; in addition, they caused an early decrease of plasma glucose followed by a hyperglycemic phase. As compared to SS-14, SS-28 elicited a longer-lasting inhibition of PP and insulin secretion and displayed greater hypo- and hyperglycemic effects. A somatostatin-like component, similar to SS-28, has been identified in pancreatic extracts as well as in peripheral plasma. Thus, it might be hypothesized that this peptide plays a role in the control of pancreatic hormone release.

Key-Words:

Somatostatin-28 - Somatostatin-14 - Pancreatic Polypeptide - Glucagon - Insulin - Glucose - Normal Subjects

      >